[1]
Pattrapornpisut P, Avila-Casado C, Reich HN. IgA Nephropathy: Core Curriculum 2021. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021 Sep:78(3):429-441. doi: 10.1053/j.ajkd.2021.01.024. Epub 2021 Jul 9
[PubMed PMID: 34247883]
[2]
Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney international. 2010 May:77(10):921-7. doi: 10.1038/ki.2010.43. Epub 2010 Mar 3
[PubMed PMID: 20200498]
[3]
Shen PC, He LQ, Tang Y, Wang Q, Wang W, Li J. Clinicopathological characteristics and prognostic factors of asymptomatic IgA nephropathy. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2010 Mar:58(3):560-5. doi: 10.231/JIM.0b013e3181d20aa1. Epub
[PubMed PMID: 20215916]
[4]
Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clinical journal of the American Society of Nephrology : CJASN. 2017 Apr 3:12(4):677-686. doi: 10.2215/CJN.07420716. Epub 2017 Feb 3
[PubMed PMID: 28159829]
[5]
Tota M, Baron V, Musial K, Derrough B, Konieczny A, Krajewska M, Turkmen K, Kusztal M. Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports. Journal of clinical medicine. 2023 Apr 6:12(7):. doi: 10.3390/jcm12072726. Epub 2023 Apr 6
[PubMed PMID: 37048809]
Level 1 (high-level) evidence
[6]
Chang S, Li XK. The Role of Immune Modulation in Pathogenesis of IgA Nephropathy. Frontiers in medicine. 2020:7():92. doi: 10.3389/fmed.2020.00092. Epub 2020 Mar 24
[PubMed PMID: 32266276]
[7]
Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, Fremeaux-Bacchi V, Novak J. Current Understanding of the Role of Complement in IgA Nephropathy. Journal of the American Society of Nephrology : JASN. 2015 Jul:26(7):1503-12. doi: 10.1681/ASN.2014101000. Epub 2015 Feb 18
[PubMed PMID: 25694468]
Level 3 (low-level) evidence
[8]
Rollino C, Vischini G, Coppo R. IgA nephropathy and infections. Journal of nephrology. 2016 Aug:29(4):463-8. doi: 10.1007/s40620-016-0265-x. Epub 2016 Jan 22
[PubMed PMID: 26800970]
[9]
Rajasekaran A, Julian BA, Rizk DV. IgA Nephropathy: An Interesting Autoimmune Kidney Disease. The American journal of the medical sciences. 2021 Feb:361(2):176-194. doi: 10.1016/j.amjms.2020.10.003. Epub 2020 Oct 8
[PubMed PMID: 33309134]
[10]
Lai KN, Tang SC, Schena FP, Novak J, Tomino Y, Fogo AB, Glassock RJ. IgA nephropathy. Nature reviews. Disease primers. 2016 Feb 11:2():16001. doi: 10.1038/nrdp.2016.1. Epub 2016 Feb 11
[PubMed PMID: 27189177]
[11]
Han SH, Kang EW, Kie JH, Yoo TH, Choi KH, Han DS, Kang SW. Spontaneous remission of IgA nephropathy associated with resolution of hepatitis A. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2010 Dec:56(6):1163-7. doi: 10.1053/j.ajkd.2010.08.018. Epub 2010 Oct 8
[PubMed PMID: 20932622]
[12]
Bhandari G, Tiwari V, Gupta A, Gupta P, Bhargava V, Malik M, Gupta A, Bhalla AK, Rana DS. IgA Nephropathy with Wilson's Disease: A Case Report and Literature Review. Indian journal of nephrology. 2021 Sep-Oct:31(5):474-477. doi: 10.4103/ijn.IJN_227_20. Epub 2021 Feb 20
[PubMed PMID: 34880558]
Level 3 (low-level) evidence
[13]
Gesualdo L, Di Leo V, Coppo R. The mucosal immune system and IgA nephropathy. Seminars in immunopathology. 2021 Oct:43(5):657-668. doi: 10.1007/s00281-021-00871-y. Epub 2021 Oct 12
[PubMed PMID: 34642783]
[14]
Canetta PA, Kiryluk K, Appel GB. Glomerular diseases: emerging tests and therapies for IgA nephropathy. Clinical journal of the American Society of Nephrology : CJASN. 2014 Mar:9(3):617-25. doi: 10.2215/CJN.07260713. Epub 2013 Sep 26
[PubMed PMID: 24071652]
[15]
Takada D, Sumida K, Sekine A, Hazue R, Yamanouchi M, Suwabe T, Hayami N, Hoshino J, Sawa N, Takaichi K, Fujii T, Ohashi K, Ubara Y. IgA nephropathy featuring massive wire loop-like deposits in two patients with alcoholic cirrhosis. BMC nephrology. 2017 Dec 13:18(1):362. doi: 10.1186/s12882-017-0769-1. Epub 2017 Dec 13
[PubMed PMID: 29237409]
[16]
Kaneko T, Arima R, Arakawa Y, Aoki M, Fukuda K, Fukui M, Hirama A, Fujita E, Mii A, Utsumi K, Shimizu A, Iino Y. [Two cases of rapidly progressive nephritic syndrome complicated with alcoholic liver cirrhosis]. Nihon Jinzo Gakkai shi. 2011:53(1):60-7
[PubMed PMID: 21370579]
Level 3 (low-level) evidence
[17]
Gouet D, Fort E, Roblot P, Maréchaud R, Sudre Y, Touchard G. [Glomerulopathy with mesangial IgA deposits in primary hemochromatosis]. La Revue de medecine interne. 1987 May-Jun:8(3):311-2
[PubMed PMID: 3616239]
[18]
Singhal J, Sharma J. IgA nephropathy secondary to liver disease. Pediatric nephrology (Berlin, Germany). 2018 Dec:33(12):2393. doi: 10.1007/s00467-018-4051-y. Epub 2018 Sep 3
[PubMed PMID: 30178238]
[19]
Abbad L, Monteiro RC, Berthelot L. Food antigens and Transglutaminase 2 in IgA nephropathy: Molecular links between gut and kidney. Molecular immunology. 2020 May:121():1-6. doi: 10.1016/j.molimm.2020.02.019. Epub 2020 Mar 2
[PubMed PMID: 32135400]
[20]
De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V, Gozzi G, Serrazanetti D, Dalfino G, Gobbetti M, Gesualdo L. Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PloS one. 2014:9(6):e99006. doi: 10.1371/journal.pone.0099006. Epub 2014 Jun 12
[PubMed PMID: 24922509]
[21]
Wei LY, Liu C, Zhang YL, Li GL. IgA nephropathy with leucocytoclastic vasculitis. The Journal of international medical research. 2018 Jul:46(7):3009-3014. doi: 10.1177/0300060518775814. Epub 2018 Jun 10
[PubMed PMID: 29888629]
[22]
Yamaguchi H, Goto S, Takahashi N, Tsuchida M, Watanabe H, Yamamoto S, Kaneko Y, Higashi K, Mori H, Nakamura Y, Horii A, Kurokawa K, Narita I. Aberrant mucosal immunoreaction to tonsillar microbiota in immunoglobulin A nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2021 Jan 1:36(1):75-86. doi: 10.1093/ndt/gfaa223. Epub
[PubMed PMID: 33099625]
[23]
Hernández JI, Gómez-Román J, Rodrigo E, Olmos JM, González-Vela C, Ruiz JC, Val JF, Riancho JA. Bronchiolitis obliterans and IgA nephropathy. A new cause of pulmonary-renal syndrome. American journal of respiratory and critical care medicine. 1997 Aug:156(2 Pt 1):665-8
[PubMed PMID: 9279256]
[24]
Jelicic I, Mladinov S. Rapidly progressive IgA nephritis and sarcoidosis. Iranian journal of kidney diseases. 2022 Sep:16(5):315-317
[PubMed PMID: 36178867]
[25]
Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, Herrmann S, Tefferi A, D'Agati VD, Nasr SH. Myeloproliferative neoplasms cause glomerulopathy. Kidney international. 2011 Oct:80(7):753-9. doi: 10.1038/ki.2011.147. Epub 2011 Jun 8
[PubMed PMID: 21654720]
[26]
Wang J, Liu Y, Liu N, Gao M, Yuan H. Paraneoplastic immunoglobulin A nephropathy in a patient with lung adenocarcinoma: A case report and literature review. The Journal of international medical research. 2021 Apr:49(4):300060521996868. doi: 10.1177/0300060521996868. Epub
[PubMed PMID: 33926295]
Level 3 (low-level) evidence
[27]
Mimura I, Tojo A, Kinugasa S, Uozaki H, Fujita T. Renal cell carcinoma in association with IgA nephropathy in the elderly. The American journal of the medical sciences. 2009 Nov:338(5):431-2. doi: 10.1097/MAJ.0b013e3181ae1b12. Epub
[PubMed PMID: 19773639]
[28]
Kiryluk K, Freedberg DE, Radhakrishnan J, Segall L, Jacobson JS, Mathur M, Mohan S, Neugut AI. Global Incidence of IgA Nephropathy by Race and Ethnicity: A Systematic Review. Kidney360. 2023 Aug 1:4(8):1112-1122. doi: 10.34067/KID.0000000000000165. Epub 2023 May 25
[PubMed PMID: 37227924]
Level 1 (high-level) evidence
[29]
McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2011 Feb:26(2):414-30. doi: 10.1093/ndt/gfq665. Epub 2010 Nov 10
[PubMed PMID: 21068142]
Level 1 (high-level) evidence
[30]
Utsunomiya Y, Koda T, Kado T, Okada S, Hayashi A, Kanzaki S, Kasagi T, Hayashibara H, Okasora T. Incidence of pediatric IgA nephropathy. Pediatric nephrology (Berlin, Germany). 2003 Jun:18(6):511-5
[PubMed PMID: 12720079]
[31]
Kiryluk K, Li Y, Sanna-Cherchi S, Rohanizadegan M, Suzuki H, Eitner F, Snyder HJ, Choi M, Hou P, Scolari F, Izzi C, Gigante M, Gesualdo L, Savoldi S, Amoroso A, Cusi D, Zamboli P, Julian BA, Novak J, Wyatt RJ, Mucha K, Perola M, Kristiansson K, Viktorin A, Magnusson PK, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boland A, Metzger M, Thibaudin L, Wanner C, Jager KJ, Goto S, Maixnerova D, Karnib HH, Nagy J, Panzer U, Xie J, Chen N, Tesar V, Narita I, Berthoux F, Floege J, Stengel B, Zhang H, Lifton RP, Gharavi AG. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS genetics. 2012:8(6):e1002765. doi: 10.1371/journal.pgen.1002765. Epub 2012 Jun 21
[PubMed PMID: 22737082]
[32]
Schena FP, Nistor I. Epidemiology of IgA Nephropathy: A Global Perspective. Seminars in nephrology. 2018 Sep:38(5):435-442. doi: 10.1016/j.semnephrol.2018.05.013. Epub
[PubMed PMID: 30177015]
Level 3 (low-level) evidence
[33]
Barbour SJ, Cattran DC, Kim SJ, Levin A, Wald R, Hladunewich MA, Reich HN. Individuals of Pacific Asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease. Kidney international. 2013 Nov:84(5):1017-24. doi: 10.1038/ki.2013.210. Epub 2013 Jun 5
[PubMed PMID: 23739233]
[34]
Soares MF, Roberts IS. IgA nephropathy: an update. Current opinion in nephrology and hypertension. 2017 May:26(3):165-171. doi: 10.1097/MNH.0000000000000312. Epub
[PubMed PMID: 28221174]
Level 3 (low-level) evidence
[35]
Magistroni R, D'Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney international. 2015 Nov:88(5):974-89. doi: 10.1038/ki.2015.252. Epub 2015 Sep 16
[PubMed PMID: 26376134]
[36]
Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, Novak J, Gharavi AG, Wyatt RJ. Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis. Kidney international. 2011 Jul:80(1):79-87. doi: 10.1038/ki.2011.16. Epub 2011 Feb 16
[PubMed PMID: 21326171]
[37]
Gharavi AG, Moldoveanu Z, Wyatt RJ, Barker CV, Woodford SY, Lifton RP, Mestecky J, Novak J, Julian BA. Aberrant IgA1 glycosylation is inherited in familial and sporadic IgA nephropathy. Journal of the American Society of Nephrology : JASN. 2008 May:19(5):1008-14. doi: 10.1681/ASN.2007091052. Epub 2008 Feb 13
[PubMed PMID: 18272841]
[38]
Yamamoto R, Nagasawa Y, Shoji T, Iwatani H, Hamano T, Kawada N, Inoue K, Uehata T, Kaneko T, Okada N, Moriyama T, Horio M, Yamauchi A, Tsubakihara Y, Imai E, Rakugi H, Isaka Y. Cigarette smoking and progression of IgA nephropathy. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2010 Aug:56(2):313-24. doi: 10.1053/j.ajkd.2010.02.351. Epub 2010 May 14
[PubMed PMID: 20471735]
[39]
Kataoka H, Ohara M, Honda K, Mochizuki T, Nitta K. Maximal glomerular diameter as a 10-year prognostic indicator for IgA nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2011 Dec:26(12):3937-43. doi: 10.1093/ndt/gfr139. Epub 2011 Mar 22
[PubMed PMID: 21427079]
[40]
Knoppova B, Reily C, Maillard N, Rizk DV, Moldoveanu Z, Mestecky J, Raska M, Renfrow MB, Julian BA, Novak J. The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy. Frontiers in immunology. 2016:7():117. doi: 10.3389/fimmu.2016.00117. Epub 2016 Apr 12
[PubMed PMID: 27148252]
[41]
Kiryluk K, Li Y, Scolari F, Sanna-Cherchi S, Choi M, Verbitsky M, Fasel D, Lata S, Prakash S, Shapiro S, Fischman C, Snyder HJ, Appel G, Izzi C, Viola BF, Dallera N, Del Vecchio L, Barlassina C, Salvi E, Bertinetto FE, Amoroso A, Savoldi S, Rocchietti M, Amore A, Peruzzi L, Coppo R, Salvadori M, Ravani P, Magistroni R, Ghiggeri GM, Caridi G, Bodria M, Lugani F, Allegri L, Delsante M, Maiorana M, Magnano A, Frasca G, Boer E, Boscutti G, Ponticelli C, Mignani R, Marcantoni C, Di Landro D, Santoro D, Pani A, Polci R, Feriozzi S, Chicca S, Galliani M, Gigante M, Gesualdo L, Zamboli P, Battaglia GG, Garozzo M, Maixnerová D, Tesar V, Eitner F, Rauen T, Floege J, Kovacs T, Nagy J, Mucha K, Pączek L, Zaniew M, Mizerska-Wasiak M, Roszkowska-Blaim M, Pawlaczyk K, Gale D, Barratt J, Thibaudin L, Berthoux F, Canaud G, Boland A, Metzger M, Panzer U, Suzuki H, Goto S, Narita I, Caliskan Y, Xie J, Hou P, Chen N, Zhang H, Wyatt RJ, Novak J, Julian BA, Feehally J, Stengel B, Cusi D, Lifton RP, Gharavi AG. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nature genetics. 2014 Nov:46(11):1187-96. doi: 10.1038/ng.3118. Epub 2014 Oct 12
[PubMed PMID: 25305756]
[42]
Roos A, Rastaldi MP, Calvaresi N, Oortwijn BD, Schlagwein N, van Gijlswijk-Janssen DJ, Stahl GL, Matsushita M, Fujita T, van Kooten C, Daha MR. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. Journal of the American Society of Nephrology : JASN. 2006 Jun:17(6):1724-34
[PubMed PMID: 16687629]
[43]
Roos A, Bouwman LH, van Gijlswijk-Janssen DJ, Faber-Krol MC, Stahl GL, Daha MR. Human IgA activates the complement system via the mannan-binding lectin pathway. Journal of immunology (Baltimore, Md. : 1950). 2001 Sep 1:167(5):2861-8
[PubMed PMID: 11509633]
[44]
Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, Sanna-Cherchi S, Men CJ, Julian BA, Wyatt RJ, Novak J, He JC, Wang H, Lv J, Zhu L, Wang W, Wang Z, Yasuno K, Gunel M, Mane S, Umlauf S, Tikhonova I, Beerman I, Savoldi S, Magistroni R, Ghiggeri GM, Bodria M, Lugani F, Ravani P, Ponticelli C, Allegri L, Boscutti G, Frasca G, Amore A, Peruzzi L, Coppo R, Izzi C, Viola BF, Prati E, Salvadori M, Mignani R, Gesualdo L, Bertinetto F, Mesiano P, Amoroso A, Scolari F, Chen N, Zhang H, Lifton RP. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nature genetics. 2011 Mar 13:43(4):321-7. doi: 10.1038/ng.787. Epub 2011 Mar 13
[PubMed PMID: 21399633]
[45]
Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA. The pathophysiology of IgA nephropathy. Journal of the American Society of Nephrology : JASN. 2011 Oct:22(10):1795-803. doi: 10.1681/ASN.2011050464. Epub 2011 Sep 23
[PubMed PMID: 21949093]
[46]
Hassler JR. IgA nephropathy: A brief review. Seminars in diagnostic pathology. 2020 May:37(3):143-147. doi: 10.1053/j.semdp.2020.03.001. Epub 2020 Mar 16
[PubMed PMID: 32241578]
[47]
Kusaba G, Ohsawa I, Ishii M, Inoshita H, Takagi M, Tanifuji C, Takahashi K, Nakamoto J, Yoshida M, Ohi H, Horikoshi S, Kurihara H, Tomino Y. Significance of broad distribution of electron-dense deposits in patients with IgA nephropathy. Medical molecular morphology. 2012 Dec:45(1):29-34. doi: 10.1007/s00795-011-0538-3. Epub 2012 Mar 20
[PubMed PMID: 22431181]
[48]
Trimarchi H, Haas M, Coppo R. Crescents and IgA Nephropathy: A Delicate Marriage. Journal of clinical medicine. 2022 Jun 21:11(13):. doi: 10.3390/jcm11133569. Epub 2022 Jun 21
[PubMed PMID: 35806856]
[49]
Kataoka H, Ohara M, Shibui K, Sato M, Suzuki T, Amemiya N, Watanabe Y, Honda K, Mochizuki T, Nitta K. Overweight and obesity accelerate the progression of IgA nephropathy: prognostic utility of a combination of BMI and histopathological parameters. Clinical and experimental nephrology. 2012 Oct:16(5):706-12. doi: 10.1007/s10157-012-0613-7. Epub 2012 Feb 17
[PubMed PMID: 22350469]
[51]
Shen P, He L, Huang D. Clinical course and prognostic factors of clinical early IgA nephropathy. The Netherlands journal of medicine. 2008 Jun:66(6):242-7
[PubMed PMID: 18689907]
[52]
D'Amico G. Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome. Seminars in nephrology. 2004 May:24(3):179-96
[PubMed PMID: 15156525]
[53]
Lai KN, Lai FM, Chan KW, Ho CP, Leung AC, Vallance-Owen J. An overlapping syndrome of IgA nephropathy and lipoid nephrosis. American journal of clinical pathology. 1986 Dec:86(6):716-23
[PubMed PMID: 3538845]
[54]
Herlitz LC, Bomback AS, Stokes MB, Radhakrishnan J, D'Agati VD, Markowitz GS. IgA nephropathy with minimal change disease. Clinical journal of the American Society of Nephrology : CJASN. 2014 Jun 6:9(6):1033-9. doi: 10.2215/CJN.11951113. Epub 2014 Apr 10
[PubMed PMID: 24721885]
[55]
Walsh M, Sar A, Lee D, Yilmaz S, Benediktsson H, Manns B, Hemmelgarn B. Histopathologic features aid in predicting risk for progression of IgA nephropathy. Clinical journal of the American Society of Nephrology : CJASN. 2010 Mar:5(3):425-30. doi: 10.2215/CJN.06530909. Epub 2010 Jan 14
[PubMed PMID: 20089495]
[56]
Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D'Agati V, D'Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney international. 2009 Sep:76(5):546-56. doi: 10.1038/ki.2009.168. Epub 2009 Jul 1
[PubMed PMID: 19571790]
[57]
Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, Massat AE, Hunley TE, Hladunewich MA, Julian BA, Fervenza FC, Cattran DC. Validation of the Oxford classification of IgA nephropathy. Kidney international. 2011 Aug:80(3):310-7. doi: 10.1038/ki.2011.126. Epub 2011 May 4
[PubMed PMID: 21544062]
Level 1 (high-level) evidence
[58]
Kang SH, Choi SR, Park HS, Lee JY, Sun IO, Hwang HS, Chung BH, Park CW, Yang CW, Kim YS, Choi YJ, Choi BS. The Oxford classification as a predictor of prognosis in patients with IgA nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012 Jan:27(1):252-8. doi: 10.1093/ndt/gfr295. Epub 2011 May 23
[PubMed PMID: 21606384]
[59]
Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J, IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Conference Participants. Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney international. 2017 May:91(5):1014-1021. doi: 10.1016/j.kint.2017.02.003. Epub 2017 Mar 22
[PubMed PMID: 28341274]
[60]
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney international. 2021 Oct:100(4):753-779. doi: 10.1016/j.kint.2021.05.015. Epub
[PubMed PMID: 34556300]
[61]
Berthoux F, Suzuki H, Thibaudin L, Yanagawa H, Maillard N, Mariat C, Tomino Y, Julian BA, Novak J. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. Journal of the American Society of Nephrology : JASN. 2012 Sep:23(9):1579-87. doi: 10.1681/ASN.2012010053. Epub 2012 Aug 16
[PubMed PMID: 22904352]
[62]
Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, Huang WQ, Anreddy SR, Hall S, Hastings MC, Lau KK, Cook WJ, Novak J. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney international. 2007 Jun:71(11):1148-54
[PubMed PMID: 17342176]
[63]
Pozzi C. Treatment of IgA nephropathy. Journal of nephrology. 2016 Feb:29(1):21-5. doi: 10.1007/s40620-015-0248-3. Epub 2015 Nov 17
[PubMed PMID: 26577268]
[64]
Takahara M, Nagato T, Nozaki Y, Kumai T, Katada A, Hayashi T, Harabuchi Y. A proliferation-inducing ligand (APRIL) induced hyper-production of IgA from tonsillar mononuclear cells in patients with IgA nephropathy. Cellular immunology. 2019 Jul:341():103925. doi: 10.1016/j.cellimm.2019.103925. Epub 2019 May 8
[PubMed PMID: 31088610]
[65]
Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J, STOP-IgAN Investigators. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. The New England journal of medicine. 2015 Dec 3:373(23):2225-36. doi: 10.1056/NEJMoa1415463. Epub
[PubMed PMID: 26630142]
[66]
Floege J, Rauen T, Eitner F. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. The New England journal of medicine. 2016 Mar 10:374(10):992-3. doi: 10.1056/NEJMc1600141. Epub
[PubMed PMID: 26962736]
[67]
Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Budde K, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J, STOP-IgAN Investigators. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney international. 2020 Oct:98(4):1044-1052. doi: 10.1016/j.kint.2020.04.046. Epub 2020 May 22
[PubMed PMID: 32450154]
[68]
Selvaskandan H, Barratt J, Cheung CK. Novel Treatment Paradigms: Primary IgA Nephropathy. Kidney international reports. 2024 Feb:9(2):203-213. doi: 10.1016/j.ekir.2023.11.026. Epub 2023 Dec 1
[PubMed PMID: 38344739]
[69]
Kittiskulnam P, Kanjanabuch T, Tangmanjitjaroen K, Chancharoenthana W, Praditpornsilpa K, Eiam-Ong S. The beneficial effects of weight reduction in overweight patients with chronic proteinuric immunoglobulin a nephropathy: a randomized controlled trial. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2014 May:24(3):200-7. doi: 10.1053/j.jrn.2014.01.016. Epub
[PubMed PMID: 24759301]
Level 1 (high-level) evidence
[70]
Wang S, Qin A, Pei G, Jiang Z, Dong L, Tan J, Tan L, Tang Y, Qin W. Cigarette smoking may accelerate the progression of IgA nephropathy. BMC nephrology. 2021 Jun 29:22(1):239. doi: 10.1186/s12882-021-02453-4. Epub 2021 Jun 29
[PubMed PMID: 34187402]
Level 2 (mid-level) evidence
[71]
Gharavi AG, Yan Y, Scolari F, Schena FP, Frasca GM, Ghiggeri GM, Cooper K, Amoroso A, Viola BF, Battini G, Caridi G, Canova C, Farhi A, Subramanian V, Nelson-Williams C, Woodford S, Julian BA, Wyatt RJ, Lifton RP. IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. Nature genetics. 2000 Nov:26(3):354-7
[PubMed PMID: 11062479]
[72]
Lv J, Xu D, Perkovic V, Ma X, Johnson DW, Woodward M, Levin A, Zhang H, Wang H, TESTING Study Group. Corticosteroid therapy in IgA nephropathy. Journal of the American Society of Nephrology : JASN. 2012 Jun:23(6):1108-16. doi: 10.1681/ASN.2011111112. Epub 2012 Apr 26
[PubMed PMID: 22539830]
[73]
Natale P, Palmer SC, Ruospo M, Saglimbene VM, Craig JC, Vecchio M, Samuels JA, Molony DA, Schena FP, Strippoli GF. Immunosuppressive agents for treating IgA nephropathy. The Cochrane database of systematic reviews. 2020 Mar 12:3(3):CD003965. doi: 10.1002/14651858.CD003965.pub3. Epub 2020 Mar 12
[PubMed PMID: 32162319]
Level 1 (high-level) evidence
[74]
Wong MG, Lv J, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Reich HN, Cattran D, Glassock R, Levin A, Jardine MJ, Wheeler DC, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V, TESTING Study Group. The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. American journal of nephrology. 2021:52(10-11):827-836. doi: 10.1159/000519812. Epub 2021 Nov 3
[PubMed PMID: 34731857]
[75]
Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V, TESTING Study Group. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2022 May 17:327(19):1888-1898. doi: 10.1001/jama.2022.5368. Epub
[PubMed PMID: 35579642]
Level 1 (high-level) evidence
[77]
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V, PROTECT Investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet (London, England). 2023 May 13:401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1
[PubMed PMID: 37015244]
Level 1 (high-level) evidence
[78]
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V, DUPRO steering committee and PROTECT Investigators. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet (London, England). 2023 Dec 2:402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3
[PubMed PMID: 37931634]
Level 1 (high-level) evidence
[79]
Smerud HK, Bárány P, Lindström K, Fernström A, Sandell A, Påhlsson P, Fellström B. New treatment for IgA nephropathy: enteric budesonide targeted to the ileocecal region ameliorates proteinuria. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2011 Oct:26(10):3237-42. doi: 10.1093/ndt/gfr052. Epub 2011 Mar 4
[PubMed PMID: 21378156]
[80]
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH, NefIgArd Trial Investigators. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney international. 2023 Feb:103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19
[PubMed PMID: 36270561]
Level 1 (high-level) evidence
[81]
Fellström BC, Barratt J, Cook H, Coppo R, Feehally J, de Fijter JW, Floege J, Hetzel G, Jardine AG, Locatelli F, Maes BD, Mercer A, Ortiz F, Praga M, Sørensen SS, Tesar V, Del Vecchio L, NEFIGAN Trial Investigators. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet (London, England). 2017 May 27:389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28
[PubMed PMID: 28363480]
Level 1 (high-level) evidence
[82]
Barratt J, Floege J. SGLT-2 inhibition in IgA nephropathy: the new standard of care? Kidney international. 2021 Jul:100(1):24-26. doi: 10.1016/j.kint.2021.04.002. Epub 2021 Apr 17
[PubMed PMID: 33878337]
[83]
Beck L, Bomback AS, Choi MJ, Holzman LB, Langford C, Mariani LH, Somers MJ, Trachtman H, Waldman M. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2013 Sep:62(3):403-41. doi: 10.1053/j.ajkd.2013.06.002. Epub 2013 Jul 18
[PubMed PMID: 23871408]
Level 2 (mid-level) evidence
[84]
Chen Y, Li Y, Yang S, Li Y, Liang M. Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review. BMC nephrology. 2014 Dec 5:15():193. doi: 10.1186/1471-2369-15-193. Epub 2014 Dec 5
[PubMed PMID: 25475967]
Level 1 (high-level) evidence
[85]
Tian L, Shao X, Xie Y, Wang L, Wang Q, Che X, Ni Z, Mou S. The long-term efficacy and safety of immunosuppressive therapy on the progression of IgA nephropathy: a meta-analysis of controlled clinical trials with more than 5-year follow-up. Expert opinion on pharmacotherapy. 2015 Jun:16(8):1137-47. doi: 10.1517/14656566.2015.1038238. Epub 2015 Apr 20
[PubMed PMID: 25892092]
Level 3 (low-level) evidence
[86]
Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC. A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction. Journal of the American Society of Nephrology : JASN. 2017 Apr:28(4):1306-1313. doi: 10.1681/ASN.2016060640. Epub 2016 Nov 7
[PubMed PMID: 27821627]
Level 1 (high-level) evidence
[87]
Coppo R. Treatment of IgA nephropathy: Recent advances and prospects. Nephrologie & therapeutique. 2018 Apr:14 Suppl 1():S13-S21. doi: 10.1016/j.nephro.2018.02.010. Epub
[PubMed PMID: 29606258]
Level 3 (low-level) evidence
[88]
Lai KN, Leung JC, Tang SC. The Treatment of IgA Nephropathy. Kidney diseases (Basel, Switzerland). 2015 May:1(1):19-26. doi: 10.1159/000381508. Epub 2015 Apr 15
[PubMed PMID: 27536661]
[89]
Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney international. 2010 Mar:77(6):543-9. doi: 10.1038/ki.2009.499. Epub 2009 Dec 23
[PubMed PMID: 20032964]
[90]
Barbour S, Feehally J. An update on the treatment of IgA nephropathy. Current opinion in nephrology and hypertension. 2017 Jul:26(4):319-326. doi: 10.1097/MNH.0000000000000336. Epub
[PubMed PMID: 28399021]
Level 3 (low-level) evidence
[91]
Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. Journal of the American Society of Nephrology : JASN. 2002 Jan:13(1):142-148. doi: 10.1681/ASN.V131142. Epub
[PubMed PMID: 11752031]
[92]
Pozzi C, Andrulli S, Pani A, Scaini P, Roccatello D, Fogazzi G, Pecchini P, Rustichelli R, Finocchiaro P, Del Vecchio L, Locatelli F. IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine. Journal of nephrology. 2013 Jan-Feb:26(1):86-93. doi: 10.5301/jn.5000110. Epub
[PubMed PMID: 22460183]
Level 1 (high-level) evidence
[93]
Maeda I, Hayashi T, Sato KK, Shibata MO, Hamada M, Kishida M, Kitabayashi C, Morikawa T, Okada N, Okumura M, Konishi M, Konishi Y, Endo G, Imanishi M. Tonsillectomy has beneficial effects on remission and progression of IgA nephropathy independent of steroid therapy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012 Jul:27(7):2806-13. doi: 10.1093/ndt/gfs053. Epub 2012 Apr 5
[PubMed PMID: 22492824]
[94]
Kumon S, Moriyama T, Kamiyama T, Karasawa K, Nitta K. The impact of tonsillectomy combined with steroid pulse therapy in patients with advanced IgA nephropathy and impaired renal function. Clinical and experimental nephrology. 2020 Apr:24(4):295-306. doi: 10.1007/s10157-019-01828-0. Epub 2019 Dec 16
[PubMed PMID: 31845064]
[95]
Ohya M, Otani H, Minami Y, Yamanaka S, Mima T, Negi S, Yukawa S, Shigematsu T. Tonsillectomy with steroid pulse therapy has more effect on the relapse rate than steroid pulse monotherapy in IgA nephropathy patients. Clinical nephrology. 2013 Jul:80(1):47-52. doi: 10.5414/CN107861. Epub
[PubMed PMID: 23557791]
[96]
Xie Y, Chen X, Nishi S, Narita I, Gejyo F. Relationship between tonsils and IgA nephropathy as well as indications of tonsillectomy. Kidney international. 2004 Apr:65(4):1135-44
[PubMed PMID: 15086452]
[97]
Watanabe-Kusunoki K, Nakazawa D, Yamamoto J, Matsuoka N, Kaneshima N, Nakagaki T, Yamamoto R, Maoka T, Iwasaki S, Tsuji T, Fukasawa Y, Nishimoto N, Nishio S, Atsumi T. Comparison of administration of single- and triple-course steroid pulse therapy combined with tonsillectomy for immunoglobulin A nephropathy. Medicine. 2021 Dec 17:100(50):e27778. doi: 10.1097/MD.0000000000027778. Epub
[PubMed PMID: 34918629]
[98]
Kamei D, Moriyama T, Takei T, Wakai S, Nitta K. Comparison between consecutive and intermittent steroid pulse therapy combined with tonsillectomy for clinical remission of IgA nephropathy. Clinical and experimental nephrology. 2014 Apr:18(2):320-8. doi: 10.1007/s10157-013-0822-8. Epub 2013 Jun 7
[PubMed PMID: 23744063]
[99]
Komatsu H, Fujimoto S. Tonsillectomy combined with steroid pulse therapy induces clinical remission of IgA nephropathy. Advances in oto-rhino-laryngology. 2011:72():57-9. doi: 10.1159/000324606. Epub 2011 Aug 18
[PubMed PMID: 21865690]
Level 3 (low-level) evidence
[100]
Adachi M, Sato M, Miyazaki M, Hotta O, Hozawa K, Sato T, Taguma Y, Katori Y. Steroid pulse therapy transiently destroys the discriminative histological structure of tonsils in IgA nephropathy: Tonsillectomy should be performed before or just after steroid pulse therapy. Auris, nasus, larynx. 2018 Dec:45(6):1206-1213. doi: 10.1016/j.anl.2018.04.009. Epub 2018 May 19
[PubMed PMID: 29789195]
[101]
Feriozzi S, Polci R. The role of tonsillectomy in IgA nephropathy. Journal of nephrology. 2016 Feb:29(1):13-9. doi: 10.1007/s40620-015-0247-4. Epub 2015 Nov 18
[PubMed PMID: 26582216]
[102]
Uffing A, Pérez-Saéz MJ, Jouve T, Bugnazet M, Malvezzi P, Muhsin SA, Lafargue MC, Reindl-Schwaighofer R, Morlock A, Oberbauer R, Buxeda A, Burballa C, Pascual J, von Moos S, Seeger H, La Manna G, Comai G, Bini C, Russo LS, Farouk S, Nissaisorakarn P, Patel H, Agrawal N, Mastroianni-Kirsztajn G, Mansur J, Tedesco-Silva H, Ventura CG, Agena F, David-Neto E, Akalin E, Alani O, Mazzali M, Manfro RC, Bauer AC, Wang AX, Cheng XS, Schold JD, Berger SP, Cravedi P, Riella LV. Recurrence of IgA Nephropathy after Kidney Transplantation in Adults. Clinical journal of the American Society of Nephrology : CJASN. 2021 Aug:16(8):1247-1255. doi: 10.2215/CJN.00910121. Epub
[PubMed PMID: 34362788]
[103]
Courtney AE, McNamee PT, Nelson WE, Maxwell AP. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2006 Dec:21(12):3550-4
[PubMed PMID: 16968729]
[104]
Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z, Wollacott AM, Suzuki Y, Pereira BJG. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney international. 2019 Jul:96(1):104-116. doi: 10.1016/j.kint.2019.01.031. Epub 2019 Mar 16
[PubMed PMID: 31027890]
[105]
Zhai YL, Zhu L, Shi SF, Liu LJ, Lv JC, Zhang H. Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy. Medicine. 2016 Mar:95(11):e3099. doi: 10.1097/MD.0000000000003099. Epub
[PubMed PMID: 26986150]
[106]
Kaartinen K, Safa A, Kotha S, Ratti G, Meri S. Complement dysregulation in glomerulonephritis. Seminars in immunology. 2019 Oct:45():101331. doi: 10.1016/j.smim.2019.101331. Epub 2019 Nov 9
[PubMed PMID: 31711769]
[107]
Rizk DV, Maillard N, Julian BA, Knoppova B, Green TJ, Novak J, Wyatt RJ. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy. Frontiers in immunology. 2019:10():504. doi: 10.3389/fimmu.2019.00504. Epub 2019 Mar 19
[PubMed PMID: 30941137]
[108]
Luvizotto MJ, Menezes-Silva L, Woronik V, Monteiro RC, Câmara NOS. Gut-kidney axis in IgA nephropathy: Role on mesangial cell metabolism and inflammation. Frontiers in cell and developmental biology. 2022:10():993716. doi: 10.3389/fcell.2022.993716. Epub 2022 Nov 17
[PubMed PMID: 36467425]
[109]
Ferri C, Puccini R, Longombardo G, Paleologo G, Migliorini P, Moriconi L, Pasero G, Cioni L. Low-antigen-content diet in the treatment of patients with IgA nephropathy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 1993:8(11):1193-8
[PubMed PMID: 8302454]